Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.1%

1 terminated out of 47 trials

Success Rate

94.1%

+7.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

6%

1 of 16 completed with results

Key Signals

1 with results94% success

Data Visualizations

Phase Distribution

35Total
Not Applicable (24)
Early P 1 (5)
P 1 (5)
P 2 (1)

Trial Status

Unknown18
Completed16
Recruiting9
Not Yet Recruiting1
Active Not Recruiting1
Terminated1

Trial Success Rate

94.1%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (47)

Showing 20 of 20 trials
NCT06465017Not ApplicableTerminated

ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer

NCT04478318Not ApplicableActive Not Recruiting

Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

NCT04983095Not ApplicableRecruiting

Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer

NCT06270394Not ApplicableCompleted

FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application

NCT05873777Not ApplicableRecruiting

68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG

NCT06387381Early Phase 1Recruiting

68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease

NCT03636607Not ApplicableWithdrawnPrimary

Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma

NCT06017973Not ApplicableRecruiting

The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus

NCT06188468Not ApplicableCompleted

ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors

NCT05610098Recruiting

Gene Expression Profiles in Spinal Tuberculosis.

NCT06558357Not Yet Recruiting

Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica

NCT03802123Phase 2CompletedPrimary

⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

NCT06203574Not ApplicableRecruitingPrimary

Clinical Study of TROP-2 PET/CT for Noninvasive Diagnosis of Solid Tumors

NCT02988531Not ApplicableCompleted

Validation of PET-MRI for Cardiovascular Disease

NCT06324890Recruiting

PET-CT Imaging Features of Meibomian Glands

NCT06203587Not ApplicableRecruitingPrimary

Clinical Study of GPA33-specific PET/CT for the Diagnosis of Colorectal Cancer

NCT03324893Not ApplicableCompleted

FCH PET/MRI Parathyroid Localization

NCT04831541Early Phase 1Unknown

68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer

NCT05188872Not ApplicableUnknownPrimary

Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE

NCT05506566Phase 1Unknown

68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies

Scroll to load more

Research Network

Activity Timeline